Small Cell Lung Cancer (SCLC)
Patient Condition
First-line Durvalumab combined with chemotherapy for extensive small cell lung cancer reached PR after 4 cycles and entered the immune maintenance treatment stage. The primary lesion was located 3.9 cm in the left lung, with liver metastases and adrenal metastases.
Treatment Timeline
| Phase | Details | Date |
|---|---|---|
| Induction period review | ||
| Immune maintenance therapy | ||
| Efficacy assessment during maintenance period | ||
| adverse reaction management |
Treatment Outcome
| before | After first-line immunization combined with chemotherapy, PR, residual focus in left lung was 1.6 cm, and metastasis in liver and adrenal glands shrank |
|---|---|
| after | The left lung lesion shrank to 0.8 cm, liver and adrenal metastases completely disappeared, close to CR, and PFS exceeded 13 months |
| highlight | After 14 cycles of Durvalumab maintenance treatment, multiple site metastases completely disappeared, close to CR, and PFS exceeded 13 months |